Home > Insider Trading > Filing (0001439222-23-000125)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc.	AGIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1312622	I Kaye Foster-Cheek	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-08-09	25,000	$18.09	36,524	No	4	M	Direct
Common Stock	Disposition	2023-08-09	25,000	$25.96	11,524	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock options (right to buy)	Disposition	2023-08-09	25,000	$0.00	25,000	$18.09

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,307		2032-06-21	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,200	Indirect	By Foster Family Revocable Trust

Footnotes

The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $25.69 to $26.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023.